Tag - LCTX


Maxim ups Lineage PT to $5 from $3

Maxim Group raised its price target for Lineage Cell Therapeutics (NYSE American:LCTX) to $5 from $3, citing an agreement with Neurgain Technologies to develop a novel parenchymal delivery injection (PDI) system for...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.